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Abstract: Objective: This study examined the predictive value of the biomarkers; Procalcitonin,
C-reactive protein, lactate, neutrophils, lymphocytes, platelets and the biphasic APTT
waveform to diagnose postoperative bacterial infection.
Design: Prospective, observational study.
Setting: A regional paediatric intensive care unit and the department of cardiac surgery
at Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom.
Patients: 368 children under the age of 16 were admitted to the PICU were enrolled in
the study. Patients not undergoing cardiac surgery were then excluded alongside those
with end stage renal or liver disease, moribund or presence of preoperative infection.
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Interventions: Blood samples for the aPTT biphasic waveform and Procalcitonin were
collected daily at the same time as part of routine investigations pre and
postoperatively until discharge. Children were assessed for postoperative infection until
day 28. We excluded children with viral infections and used the Chi-squared test,
Mann-Whitney U test, independent sample t test and logistic regression models to
determine the predictive value of the biomarkers in those with and without infection.
Measurements and Main Results: In total 89/368 (24%) of the children developed
bacterial infections (BI) post-operatively, the majority being surgical site infections.  In
those with BI, Procalcitonin was elevated on post-operative days one, three and the
last measurement prior to event (LMPTE). The most significant difference was the
LMPTE, 0.67ng/ml in the BI group vs 0.13ng/ml in the non-BI group (p<0.001).
Longitudinal profiles of PCT and lymphocytes were indistinct in the BI and non-BI
groups.
Conclusion: None of the biomarkers studied within three days of infection
demonstrated a strong predictive value, distinguishing between infection and SIRS in
this patient group remains to be difficult.
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Dear Prof. Patrick M. Kochanek (Editor-in-Chief),  
 
 
We are pleased to submit our manuscript: Identifying children in the intensive care unit at risk 
of postoperative bacterial infection following cardiothoracic surgery by D’Souza et al., for 
consideration for publication as an original article in Pediatric Critical Care Medicine.   
This study reports a large prospective cohort study evaluating seven biomarkers of 
infection (procalcitonin (PCT), C-reactive protein (CRP), lactate, neutrophils, lymphocytes, 
platelets and the biphasic APTT waveform) in 368 children admitted to intensive care following 
elective cardiac surgery.  In those children who developed bacterial infection following surgery, 
the most significant difference was seen with PCT in the last measurement prior to developing 
infection (0.72ng/ml in the bacterial infection group versus 0.13ng/ml in group with no infection, 
vs 0.46ng/ml in the culture-negative group, vs 0.09ng/ml viral infection group). The longitudinal 
profiles highlighted that dynamic changes in PCT are more significant than absolute values in 
distinguishing between the patient groups. An interesting finding from the study was that in 
those with culture-negative sepsis, PCT increases rapidly in the first two postoperative days 
before gradually falling until postoperative Day 5, this was distinct to the other patient groups 
up to postoperative Day 5.  
The findings highlighted demonstrate that PCT has faster kinetics than CRP following 
cardiac surgery and suggest that PCT levels that fail to decrease sufficiently within the first 
few days postoperatively could indicate an infectious aetiology, this is similar to the findings 
by Harponiuk et al in 51 children (1) and Jaworski et al in 60 children (2). This could help guide 
rational antibiotic use by allowing the earlier discontinuation of antibiotics in children where 
PCT levels fall rapidly after postoperative Day 2. This confers some of the findings by Li et al 
that dynamic longitudinal monitoring of PCT is more valuable than absolute values and that 
differentiating infection from cardiopulmonary bypass (CPB)-induced SIRS remains 
challenging (3). Our study remains unique in the fact that we are the largest study worldwide 
having enrolled 368 children in four separate patient groups (bacterial infection, viral infection, 
Cover Letter
culture negative sepsis and no infection) alongside conducting a detailed secondary analysis 
considering microbiology, site of infection, ventilator-free days 28 (VFD-28) amongst others. 
Furthermore, we were able to apply the serial data to the prediction of clinically meaningful 
outcomes, as would occur in routine clinical practice. 
We confirm that the manuscript has not been published elsewhere and no other 
papers based on this work have been submitted. The paper is not under consideration by 
another journal and should it be published in Pediatric Critical Care Medicine it will not be 
published elsewhere without permission of the editors. All authors have taken a significant 
role in the conceptualization and completion of the research and have approved the 
manuscript, agreeing with its submission to Pediatric Critical Care Medicine. 
 
Yours Sincerely  
 
Shane D’Souza 
Corresponding author 
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ABSTRACT  
Objective: Following surgery, it is difficult to distinguish a post-operative inflammatory 
reaction from infection. This study examined the predictive value of the biomarkers; 
procalcitonin (PCT), C-reactive protein (CRP), lactate, neutrophils, lymphocytes, platelets and 
the biphasic APTT waveform in diagnosing bacterial infection following cardiac surgery. 
Design: Prospective, observational study.  
Setting: A regional, Paediatric Intensive Care Unit (PICU) in the United Kingdom. 
Patients: 368 children under the age of 16 admitted to the PICU for elective cardiac 
surgery were enrolled in the study.  
Interventions: All biomarker measurements were determined daily until post-
operative Day 7. Children were assessed for post-operative infection until day 28 and divided 
into four groups: bacterial infection (BI), culture negative sepsis, viral infection and no infection. 
We used the Kruskal-Wallis test, Chi-squared test, Analysis of variance (ANOVA), and Area 
under the curve (AUC) in our analysis.  
Measurements and Main Results: In total, 71/368 (19%) children developed BI post-
operatively, the majority being surgical site infections.  In those with BI, PCT was elevated on 
post-operative Days 1-3 and the last measurement prior to event (LMPTE) compared to those 
without BI. The most significant difference was the LMPTE; 0.72ng/ml in the BI group versus 
0.13ng/ml in the no infection group (for all groups, p<0.001). Longitudinal profiles of all 
biomarkers were indistinct in the BI and non-BI groups except in those with culture-negative 
infections who had distinct PCT kinetics on post-operative Days 1-4. Children with culture-
negative sepsis required longer ventilatory support and PICU stay and were more likely to 
develop complications than the other groups. 
Conclusion: None of the biomarkers studied within three days of infection 
distinguished between infection and post-operative inflammatory reaction. However, PCT 
kinetics peaked on post-operative Day 2 and fell more sharply than CRP kinetics, which 
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peaked at post-operative Day 3. The monitoring of PCT kinetics following cardiac surgery may 
help guide rational antimicrobial use. 
 
INTRODUCTION 
Sepsis, now defined as life-threatening organ dysfunction caused by a dysregulated host 
response to infection, presents a significant disease burden, resulting in increased morbidity, 
mortality, and length of Paediatric Intensive Care Unit (PICU) and hospital stay. Sepsis is a 
major health concern and it is estimated that 60% of deaths in children under the age of five 
are attributed to sepsis (1, 2).  
The systemic inflammatory response syndrome (SIRS) is a common finding after 
cardiothoracic surgery, where the problem lies in distinguishing between an invasive bacterial 
infection – requiring antibiotic therapy - or a general systemic response to the stress of cardiac 
surgery. SIRS and sepsis often present with closely related clinical signs and significant 
overlap in presentation, thus, making it difficult to distinguish the two entities even with 
investigations (Figure 1). Currently, laboratory investigations requested typically include a full 
blood count (FBC), C-Reactive protein (CRP), alongside bacterial cultures, and viral 
polymerase chain reaction (PCR) of respiratory secretions (3). However, bacterial cultures - 
the gold standard for diagnosis, may take 24-48 hours to ascertain the diagnosis.  
Accurate and sensitive biomarkers of bacterial infection, providing prognostic 
information in real time are needed. Clinicians need to prescribe antibiotics to patients 
displaying SIRS before confirmation of bacterial infection, as delays in initiating treatment for 
invasive bacterial infection could lead to life-threatening complications. The overuse of 
antibiotics contributes to the development of antimicrobial resistance, a global health 
emergency. Antimicrobial resistance is associated with increased hospital costs due to 
hospital-acquired-infections caused by multidrug resistant organisms and result in in 
increased morbidity, mortality, and prolonged hospital stay. In the paediatric population, 
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studies have shown that nosocomial infection cause 20-30% of post-operative complications 
(4).  
Procalcitonin (PCT) is a 116-amino acid precursor of the hormone calcitonin, it is 
synthesised by the thyroid C cells and pulmonary endocrine cells. In normal health and 
physiology, it is undetectable in serum. Half-life is approximately 24 hours and independent of 
renal excretion, research shows that TNFα (as well as IL-1β and IL-6) stimulate PCT release 
(5). Therefore, PCT is not elevated in viral or fungal infections as it is only released in response 
to bacteria-specific proinflammatory mediators.  
Early in-vitro experimental studies have demonstrated a reduced morbidity and 
mortality in animals injected with PCT antibodies (6).  Studies in children demonstrate that a 
combined longitudinal measurement of PCT and WCC showing dynamic elevation across 
post-operative days one through three are significant at differentiating infection from 
cardiopulmonary bypass (CPB)-induced SIRS (7, 8). However, PCT levels can be increased 
in other clinical scenarios such as organ rejection, acute respiratory distress syndrome and 
pancreatitis (9).  
Other biomarkers such as the biphasic activated partial thromboplastin time (bAPTT) 
reflects light transmittance changes in human plasma, which has been shown to be altered in 
patients with sepsis, presenting a biphasic waveform. This waveform occurs because there is 
a formation of calcium-dependent complexes between CRP and very low density lipoproteins 
(VLDL), the resulting consequence is that light transmission decreases before a clot is formed 
in the first part of the curve (10).  As a clinical biomarker, bAPTT in combination with PCT has 
the potential to be sensitive and specific marker of bacterial sepsis (10). 
CRP and platelets are acute phase reactants (APRs) released in response to an 
inflammatory insult. APRs decrease or increase by 25% during an inflammatory state or tissue 
injury (11). High CRP levels are not reliable as they represent inflammation for many causes, 
and not simply infection. A secondary thrombocytosis may occur due to elevated levels of 
proinflammatory cytokines that are released in response to a tissue insult (12).  
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Study aims 
The aim of this study was to determine the predictive values of seven biomarkers 
(Procalcitonin (PCT), Biphasic aPTT waveform (bAPTT), C-Reactive Protein (CRP), Lactate, 
Platelets, Neutrophils and Lymphocytes) to diagnose bacterial infection (BI) post-operatively 
in children undergoing cardiac surgery. 
The secondary aim of the study was to determine the value of the biomarkers in 
predicting complications such as Time to discharge, Bypass time, Antibiotic duration, PICU-
free days (PFD-28), Ventilator-free days (VFD-28), Multiple organ dysfunction syndrome 
(MODS), Disseminated intravascular coagulation (DIC), and inotrope score at 12 hours. 
 
METHODS  
The study was designed as a single-centre prospective case-control study which aimed to 
determine the utility of biomarkers in the early detection of BI in children admitted to PICU at 
Alder Hey Children’s NHS Foundation Trust in Liverpool (United Kingdom) between October 
2010 and June 2012. Alder Hey is a tertiary paediatric centre, covering a paediatric population 
of over one million children.  In total, the study enrolled 657 patients between 0-16 years old; 
of whom 473 children had undergone surgery, 368 of whom had undergone cardiac surgery. 
None of them had a BI at admission (Figure 2).  
The seven biomarkers (Procalcitonin (PCT), Biphasic aPTT waveform (bAPTT), C-
Reactive Protein (CRP), Lactate, Platelets, Neutrophils and Lymphocytes), were measured 
daily for seven days following PICU admission from blood samples collected at the same 
time as routine investigations.  All assays were carried out using validated or automated 
methods.  PCT was measured using an automated analyser (KRYPTOR-TRACE 
technology, BRAHMS, Germany). The aPTT biphasic waveform was measured using a 
MDA-180 analyser (Trinity Biotech UK, Ireland). CRP was measured using an 
immunoturbidimetric assay on an automated Abbott Architect analyser.  Clinicians were 
blinded to the results of PCT, and bAPTT, which were measured in batches at a later date.  
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The presence and timing of sepsis was defined according to definitions of the American 
College of Chest Physicians/Society of Critical Care Medicine (ACCP/SCCM) with adaptation 
to children by The International Paediatric Sepsis Conference, 2002 (13). We allocated the 
patients in to four groups – BI, culture negative sepsis, viral infection and no infection based 
on the classification of their first infectious episode. Further episodes of infection were 
excluded from the analysis.  
Clinical definitions were based on best practise according to the Centers for Disease 
Control and Prevention (CDC) (14-17), final adjudication of diagnoses was by a 
multidisciplinary clinical team who met twice weekly to review PICU cases. The clinical 
multidisciplinary team consisted of clinicians from PICU, paediatric infectious disease and 
microbiology. 
 
Definitions  
Bacterial infection (BI): children with a definite bacterial infection or a definite bacterial-viral 
infection as indicated by a positive culture or PCR from a normally sterile site (17). Additionally, 
we allocated those with presumed bacterial infection to the BI group. This was defined by 
clinical findings based on a negative surgical site culture but active wound dehiscence or 
sloughing and purulent drainage from the surgical site. 
Culture-negative sepsis: children presenting with signs of sepsis but negative culture 
or PCR from a sterile site.  
Viral infections (VI): children whose infections were confirmed by viral PCR. 
No infection: these children had negative cultures and no clinical signs of infection.  
Community acquired infection (CAI): was defined as infection that was detected 
within the first 48 hours of admission (18).  
Healthcare associated infections (HAI) were defined as those that occurred > 48 
hours after admission (18).  
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Ventilator associated pneumonia (VAP): where the patient is on mechanical 
ventilation for >2 calendar days on the date of event, with day of ventilator placement being 
Day 1, *AND the ventilator was in place on the date of event or the day before (15).  
Central line associated bloodstream infection (CLABSI): was defined as a positive 
blood culture in a patient with a central line (central venous catheter) at the time of (or within 
48-hours prior to) the onset of symptoms. Central lines were either a peripherally inserted 
central catheter (PICC) line, a tunneled catheter or an implanted port (17). 
Urinary tract infection (UTI): included symptomatic UTI and catheter-associated UTI, 
we excluded asymptomatic bacteriuria (17). 
Device associated infection (DAI): was defined as the three most common device-
associated infections; central line-associated bloodstream infection (CLABSI), ventilator-
associated pneumonia (VAP) and catheter-associated urinary tract infection (CAUTI) (17). 
Surgical site infection (SSI): Date of event for infection occurs within 30 days after 
any operative procedure (where Day 1 = the procedure date) and involves only skin and 
subcutaneous tissue of the incision and patient has at least one of the followings: 
a. purulent drainage from the superficial incision. 
b. organisms identified from an aseptically-obtained specimen from the superficial incision or 
subcutaneous tissue by a culture or non-culture based microbiologic testing method which is 
performed for purposes of clinical diagnosis or treatment. 
c. superficial incision that is deliberately opened by a surgeon, attending physician or other 
designee and culture or non-culture based testing is not performed and patient has at least 
one of the following signs or symptoms: pain or tenderness; localized swelling; erythema; or 
heat (14). 
Other infection site: was defined as infection that was from multiple or unknown sites, 
including cultures for gastroenteritis, conjunctivitis, and other respiratory infections.  
Multiple organ dysfunction syndrome (MODS): according to the definitions of the 
ACCP/SCCM Consensus Conference Committee, primary MODS describes an insult in which 
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organ dysfunction occurs early and can be attributable to it, whereas secondary MODS is the 
consequence of a host response, in the context of SIRS or sepsis (13). 
Disseminated intravascular coagulation (DIC): was defined based on laboratory 
values indicating low platelets and a raised prothrombin/activated partial thromboplastin time. 
We decided to exclude a subsection of patients due to diagnostic uncertainty where 
there wasn’t undisputable evidence of bacterial infection (based on clinical appearance of the 
wound or where there was no comment) (n=10).  
Data was presented as medians and interquartile ranges for all non-normally 
distributed variables. Receiver operator curves (ROC) were constructed to explore possible 
thresholds for the diagnosis of infection. Furthermore, we used logistic regression models for 
predictive analyses, the Chi-squared test for categorical demographic data, the Mann-Whitney 
U test for continuous data not normally distributed and the Kruskal-Wallis test when making 
comparisons between the four groups. 
 
RESULTS 
Patient demographics 
From October 2010 to June 2012, 368 patients who underwent cardiac surgery were recruited 
to the study, a total of 119 patients went on to develop an infection of which 71 were bacterial 
infections, viral infections (n=24) and culture-negative sepsis (n=24). In total, 42 different 
primary ICD10 diagnoses were recorded. The most common isolated defects were septal 
pathologies which accounted for 27% of patients. Tetralogy of Fallot, patent ductus arteriosus, 
atrial or ventricular septal defects and Down syndrome-related defects accounted for almost 
50% of patients.  
In total 20% of the patients were admitted from other hospitals and 28-day mortality 
was less than 1%. Preoperative baseline characteristics were similar in both those with 
infection and those without, all children were followed up until day 28 including four who were 
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followed until death. The demographic differences between children with BI and those in the 
remaining three groups are highlighted in Table 1. The demographics showed that those with 
BI were younger in age, median 5 months vs 7 months (no infection) vs 27 months (culture-
negative) vs 5 months (viral infection) (p<0.02).  
 
Intraoperative progress 
Children with culture-negative sepsis spent the longest time in the PICU, 17 PICU-free days 
(days alive and free from the need for intensive care in the first 28 days) followed by those 
with BI who spent longer in the PICU (21 PICU-free days) than the other groups; 25 free days 
(no infection) vs 22.5 (viral) (p<0.001). Similarly, those with culture-negative sepsis spent the 
longest time on ventilatory support, 21 ventilator-free days (days when ventilation was not 
used in airway management) in the first 28 days post-operation followed by BI with 23 free 
days vs 26 days (no infection) vs 24 days (viral infection) (p<0.001). A total of 88% (n=324) of 
children underwent cardiopulmonary bypass. The longest cardiopulmonary bypass time was 
found in those with culture-negative sepsis, 153 minutes vs 132 (BI) vs 101 (no infection) vs 
82 (viral infection) (p=0.003); cross-clamp time was indistinct across patient groups. 
 
Type of infections and infection sites  
In total, 119 suspected infections, were identified (Table 2) including confirmed bacterial and 
viral infections, bacterial-viral co-infection, presumed bacterial infection and culture-negative 
sepsis. For the analysis presented here, only confirmed bacterial infections (n=71) including 
bacterial-viral co-infection are included (BI). BI accounted for 19% of infections in all patients, 
viral infections (6.5%, n=24), culture negative sepsis (6.5%, n=24) and no infection (65%, 
n=239) as shown in Table 2. For all infections, the most common site of infection for those 
with BI was the surgical site (n=43, 61%) followed by unknown/other infection site (n=15, 21%) 
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and cumulatively, DAI (n=13, 18%). HAI accounted for the majority of infections whilst around 
10% were community acquired. Of the 119 infections, 42 led to SIRS (35%) (Table 3).  
 In total, 59 infections occurred before postoperative Day 8 (BI = 26, culture negative = 
16 and VI = 17), whilst 60 infections occurred on or after postoperative Day 8 (BI = 45, culture 
negative = 8 and VI = 7). We found the AUC curves for infections occurring up to postoperative 
Day 8 unremarkable with Procalcitonin on Day 1 (0.59 (0.52, 0.65)), Day 2 (0.57 (0.50, 0.65)) 
and Day 3 (0.59 (0.50, 0.68)). 
We found that several of the biomarkers did not accurately differentiate between BI 
and non-BI groups as illustrated in Table 3. Procalcitonin was increased on the first two days 
preceding diagnosis of an infection in the BI group. The bAPTT waveform, neutrophils, 
platelets and lymphocytes showed no significant difference between the BI and non-BI groups 
of patients. 
Furthermore, the graphs depicting longitudinal monitoring do not show differential 
changes days post-operatively in the BI group for all biomarkers compared to the other patient 
groups (Fig 3). For patients with BI, PCT values showed a 59% drop between day two and 
day four postoperatively which was similar to a decrease of 60% in the non-BI group. For CRP, 
patients with BI had a decrease in CRP by 59% between day two and day four which was 
again similar to a decrease of 60% in the non-BI group.  In those with culture-negative sepsis, 
PCT and CRP dynamics were distinct on postoperative Days 1-5 compared to the other patient 
groups. The other biomarkers showed no significant differences between the groups. 
 
Secondary outcome measures 
Children with BI were more likely to have MODS which occurred in 20% (n=14) versus 3% in 
the non-BI group (p<0.001). Similarly, DIC was more common in the BI group 24% (n=17) 
versus 13% in the non-BI group (p=0.04). The median length of admission for all patients were 
21 PICU-free days 28 (PFD28). CPB, increased cross-clamp time, elevated levels of lactate 
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and PCT were associated with DIC. CRP, neutrophils, and platelets decreased on all post-
operative days in those who developed DIC.  
The sub-analysis for MODS showed levels of lactate, PCT, neutrophils, PICU stay 
duration, CPB, cross-clamp time and duration of ventilation were all significantly increased in 
children with MODS. Platelet counts were significantly lower in the MODS group across all 
post-operative days. Other biomarkers showed no statistical significance between patient 
groups.  
 
DISCUSSION 
In this single-centre, prospective cohort study none of the biomarkers studied were 
significantly elevated in the days preceding infection. In those with BI, the most significant 
difference was the LMPTE for PCT, 0.72ng/ml in the BI group versus 0.13ng/ml (no infection) 
vs 0.46ng/ml (culture-negative) vs 0.09ng/ml (viral infection) (p<0.001). The longitudinal 
profiles highlight that dynamic changes in PCT are more significant than absolute values in 
distinguishing between the patient groups. For all infections occurring prior to postoperative 
Day 7 and for all infections occurring prior to postoperative Day 28, our AUC values were 
indiscriminate. 
An interesting finding was that in those with culture-negative sepsis, PCT increases 
rapidly in the first two postoperative days before gradually falling until postoperative Day 5, 
this was distinct to the other patient groups up to postoperative Day 5. The culture-negative 
sepsis group is a more homogeneous group than the BI, as this is a group of children with 
signs of sepsis and ill enough to be admitted to a PICU, which suggests that there is 
generalised systemic inflammation and possibly organ dysfunction. A total of 38% of those 
with culture-negative sepsis went on to develop MODS (n=9) versus 20% of those with BI 
(n=14). By contrast the BI group includes children with SSI, which is a localised infection, and 
which for most of the cases occurred after postoperative Day 7 when the PCT was not 
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measured daily, and there was no differential longitudinal profile between BI and non-BI. 
Although CRP peaked on postoperative Day 3 in the culture-negative sepsis group, it was 
indistinct for those with BI. The findings highlighted demonstrate that PCT has faster kinetics 
than CRP following cardiac surgery and suggest that PCT levels that fail to decrease 
sufficiently within the first few days post-operatively could indicate an infectious aetiology. 
These findings could help guide rational antibiotic use, by allowing the earlier discontinuation 
of antibiotics in children where PCT levels fall rapidly after postoperative Day 2. Our findings 
are in line with those found in other papers where PCT has been monitored longitudinally (8, 
19-22). Furthermore, the kinetics of children who were in the culture-negative group mirrored 
that would be expected of a bacterial infection, suggesting that microbiological diagnostics are 
failing to confirm a bacterial aetiology, yet clinician acumen suggests using antibiotics in this 
patient group. 
CRP, neutrophils, lymphocytes, bAPTT and platelets showed no significant variation 
between all patient groups. An explanation for this could be attributed to the major stress 
placed on the body by surgery and bypass, lymphocyte redistribution is common post-surgery 
and results in a lymphopenia (23).  
When we compared the demographics of the BI and non-BI group, we found that those 
in the BI group were younger, this can be associated with an immature immune system. Those 
infected spent longer in the PICU, with a shorter number of PICU free days-28. One potential 
explanation is that MODS was increased in the BI group compared to the other patient groups. 
Furthermore, a prolonged period on ventilatory support and a prolonged bypass time were 
also significantly elevated in the infection group, ventilator associated pneumonia accounted 
for 14% of infections in the cohort. 
In view of this, preventative strategies to reduce post-operative infection, early and 
accurate diagnosis and prompt treatment would positively impact on utilisation of PICU and 
hospital resources. Infection prevention and control strategies such as perioperative care 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 13 
 
bundles (24), aseptic non-touch technique (25), isolation and the correct use and disposal of 
personal protective equipment are essential (26) .  
PCT and lactate were raised across all postoperative days for patients whom had 
MODS. Children with DIC had a significantly raised lactate across postoperative Day 1/2 and 
LMPTE, whereas CRP was decreased across postoperative Day 2/3 in the DIC group. PCT 
was consistently elevated postoperatively and on the LMPTE in the DIC group. Those with 
DIC had a prolonged PICU stay, bypass time, cross-clamp time, duration of ventilation and 
longer duration of antibiotics. 
An interesting observation from the study was that children with culture-negative 
sepsis had the longest cardiopulmonary bypass time, the longest duration of ventilation, the 
longest duration of antibiotic treatment and the longest PICU stay. As highlighted above, this 
group of children were likely to be very unwell, with a generalised host response and possible 
organ dysfunction, so this is not surprising. The longitudinal kinetics for this group showed 
dynamic increases in PCT, CRP and neutrophils. Clinical judgement of treating this patient 
group in the same manner as those with BI is justified and adumbrates the need for more 
sensitive microbiology diagnostics to guide antibiotic prescription and duration.  
The strengths of our study were that we investigated a large cohort of patients 
undergoing a range of cardiothoracic operations. We believe that this is the largest published 
cohort comparing the most biomarkers, measured longitudinally in children undergoing 
cardiac surgery. Around 12% of patients did not undergo cardiopulmonary bypass (CPB). This 
makes our results more generalisable. We measured seven biomarkers longitudinally as well 
as collected comprehensive data on other outcomes such as DIC and MODS. This makes our 
study unique in that we were able to apply the serial data to the prediction of clinically 
meaningful outcomes, as would occur in routine clinical practice. 
Our study has some limitations, firstly, a small minority of patients did not receive daily 
biomarker measurements due to discrepancies with families and clinician led decisions. 
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Secondly, patients with bacterial and mixed viral-bacterial infections were all grouped together 
to increase the sample size, some biomarkers are more sensitive to bacterial infections and 
would not necessarily be elevated in those with co-infections. Finally, as the biomarkers were 
mostly only measured to postoperative Day 7, a large proportion of patients developed an 
infection after hospital discharge making the LMPTE difficult to interpret. Without serial 
measurements after postoperative Day 7, the LMPTE for over 50% of patients (n=60) would 
have been obtained when the patient was clinically aseptic and recovering from the stressors 
placed on the body by cardiac surgery. Furthermore, the different types and sources of 
infection occur at different dates after cardiac surgery, for instance, SSI, which commonly 
occur between 1-2 weeks postoperatively. 
 
CONCLUSION 
Differentiating between an infection and post-operative inflammation continues to remain 
difficult in this patient group. Longitudinal monitoring was indistinct for those with BI, however, 
our study showed distinct PCT and CRP kinetics up to postoperative Day 5 in those with 
culture-negative sepsis. Longitudinal measurements of PCT and CRP and monitoring its 
dynamic changes provide valuable information and should be considered in the decision-
making process to guide rational antibiotic use postoperatively. Children with an infection were 
more likely to be of a younger age with a prolonged CPB time, increased PICU stay, extended 
periods of ventilation and susceptible to further complications of MODS and DIC.  
 
FIGURES 
Figure 1: Schematic showing the overlap between infection, SIRS and sepsis  
Figure 2: CONSORT Diagram and patient flow diagram for study procedures 
Figure 3. Serial mean biomarker measurements in children with bacterial infection (solid line) 
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and without infection (dashed line) during the first seven postoperative days.  
 
 LEGENDS 
Table 3: Biomarker values in the three days preceding infection (where infection 
occurs on day three) 
1Due to the large number of infections occurring post-discharge, we have displayed infections 
occurring within the first three critical post-operative days as this is when antibiotics are commonly 
initiated in post-operative prophylaxis (n=34 patients)  
Figure 3. Serial mean biomarker measurements in children with bacterial 
infection (solid line) and without infection (dashed line) during the first seven 
postoperative days.  
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Table 1 
Variables No 
infection 
Bacterial Culture-
negative 
Viral Significance  
Gender    n(%)                                                          
Female                                                                           
Male 
119 (49.0) 
120 (50.2) 
26 (39.4)
43 (60.6) 
 
12 (50.0) 
12 (50.0) 
 
9 (33.3) 
16 (66.7) 
 
P=0.243 
Age (months)1                                            6.84 (34.1)
0.12-194 
5.40 (17.0) 
0.08-162 
27.1 (97.7) 
0.12-180 
5.28 
(8.16) 
0.84-92.8 
P=0.024 
Time to surgery 
from admission 
(days)1                        
1 (1) 
0-31 
1 (3) 
0-32 
1 (1) 
0-9 
1 (0) 
0-4 
NA 
Time to discharge 
from the intensive 
care unit (days)1 
3 (4) 
1-168 
7 (11) 
1-63 
11 (13) 
1-41 
5.5 (14) 
3-39 
NA 
Time from surgery 
to infection (days)1 
 8 (10) 
0-28 
2 (4) 
0-15 
1.5 (8) 
0-26 
NA 
Paediatric intensive 
care unit free days-
28 (days)1 
25 (4) 
0-27 
21 (11) 
0-27 
17 (13) 
0-27 
22.5 (14) 
0-25 
P<0.0014 
Bypass (minutes)1         101 (82) 
0-321 
132 (106) 
0-273 
153 (132) 
0-360 
82 (98) 
0-264 
P=0.0034 
Clamp (minutes)1                                         62 (66) 
0-272 
75 (86) 
0-208 
84 (130) 
0-231 
56.5 (105) 
0-211 
P=0.624 
Multiple organ 
dysfunction 
syndrome (n(%))             
No                                                                           
Yes 
 
 
 
231 (96.7)
8 (3.3) 
 
 
 
57 (80.3)
14 (19.7) 
 
 
 
15 (62.5) 
9 (37.5) 
 
 
 
20 (83.3) 
4 (16.7) 
 
 
 
NA 
Disseminated 
intravascular 
coagulation (n(%))         
No                                                                                
Yes 
 
 
 
207 (986.6)
32 (13.4) 
 
 
 
54 (76.1)
17 (23.9) 
 
 
 
19 (79.2) 
5 (20.8) 
 
 
 
21 (87.5) 
3 (17.5) 
 
 
NA 
Mechanical 
ventilation (days)1 
0.74 (2) 
0-121 
3.25 (6) 
0-31 
5.39 (11) 
0-25 
2.15 (5) 
0-18 
NA 
Ventilator free days-
28 (days)2 
26.20 
(3.21) 
23.29 
(5.69) 
21.38 (7.10) 23.93 
(4.56) 
P<0.0015 
Duration of 
antibiotics (days)1                             
2 (1) 
1-18 
3 (7) 
1-29 
7 (7) 
2-24 
2 (3) 
2-18 
NA 
 
1 Median (IQR) and range 
2 Mean (standard deviation)  
3 Chi-squared test  
4 Kruskal-Wallis test  
5 ANOVA 
NA – formal statistical test not applicable due to zeros or small counts in some cells.  
 
Table
Table 2 
Type of  suspected 
infection 
 
Number of patients (n=368) 
 
No infection 239 
 
Confirmed bacterial 
infection 
 
71 
Culture-negative 24 
 
Viral infection 24 
 
Site of infection 
Number of infections, 
(n=119) 
Bacterial 
infection 
(n=71) 
 
Culture 
negative 
(n=24) 
 
Viral 
infection 
(n=24) 
Ventilator associated 
pneumonia (VAP) 
 
19 (16%) 7 (10%) 9 (37%) 3 (13%) 
Central line associated 
bloodstream infection 
(CLABSI) 
 
7 (6%) 6 (8%) 1 (4%) 0 
Blood stream infection 
(BSI) 
 
0 0 0 0 
Catheter associated 
Urinary tract infection 
(CAUTI) 
 
0 0 0 0 
Surgical site infection 
(SSI) 
 
49 (41%) 43 (61%) 3 (13%) 3 (13%) 
Other infection site 44 (37%) 15 (21%) 11 (46%) 18 (74%) 
Device associated 
infection (DAI) 
 
26 (22%) 13 (18%) 10 (41%) 3 (13%) 
 
NB: We decided to exclude a subsection of patients due to diagnostic uncertainty 
where there wasn’t undisputable evidence of bacterial infection (based on clinical 
appearance of the wound or where there was no comment left by clinicians) (n=10) 
 
Table
Table 3 
Biomarker and 
postoperative  day of 
measurement 
No infection 
(median, (IQR)) 
Bacterial 
infection 
(median, 
(IQR)) 
Culture 
negative 
(median, 
(IQR)) 
Viral infection 
(median, (IQR)) 
Area under the 
curve (95% CI) 
 
 
Procalcitonin Day 1 0.09 (0.23) 0.16 
(0.47) 
 
0.17 (0.54) 
 
0.08 (0.17) 0.59 (0.52, 0.65) 
 
Procalcitonin Day 2 1.40 (2.56) 1.70 
(4.34) 
 
4.00 (19.43) 1.62 (2.67) 0.57 (0.50, 0.65) 
 
Procalcitonin Day 3 0.80 (1.38) 1.47 
(3.20) 
1.60 (16.27) 0.95 (2.08) 0.59 (0.50, 0.68) 
bAPTT Day 1 -0.0015 (0.03) -0.0027 
(0.03) 
 
-0.0003 
(0.03) 
 
-0.0036 (0.03) 
 
0.49 (0.42, 0.56) 
 
bAPTT Day 2 -0.0142 (0.03) -0.006 
(0.03) 
 
-0.0377 
(0.07) 
 
-0.0131 (0.03) 
 
0.51 (0.44, 0.58) 
 
bAPTT Day 3 
 
-0.0136 (0.03) -0.0226 
(0.04) 
-0.0567 
(0.10) 
-0.0168 (0.08) 0.39 (0.31, 0.47) 
Neutrophils Day 1 6.68 (4.94) 7.25 
(6.35) 
 
7.69 (3.09) 6.50 (5.33) 0.49 (0.42, 0.55) 
Neutrophils Day 2 8.16 (4.62) 9.16 
(4.94) 
 
11.15 (4.70) 8.01 (3.47) 0.61 (0.53, 0.68) 
Neutrophils Day 3 
 
7.07 (3.93) 7.13 
(4.05) 
9.54 (6.46) 5.06 (3.99) 0.52 (0.43, 0.61) 
Platelets Day 1 136 (86) 144 (120) 124 (99) 120 (155) 0.50 (0.43, 0.56) 
Platelets Day 2 141 (77) 165 (87) 121.5 (59) 146 (111) 0.51 (0.43, 0.58) 
Platelets Day 3 
 
146.5 (101) 140 (74) 120 (64) 149 (1060) 0.43 (0.34, 0.51) 
Lymphocytes Day 1 1.81 (1.68) 2.01 
(1.87) 
 
1.09 (0.69) 
 
2.47 (2.40) 0.47 (0.40, 0.54) 
Lymphocytes Day 2 2.52 (1.86) 2.32 
(1.73) 
 
1.69 (1.70) 
 
2.62 (1.75) 0.47 (0.40, 0.55) 
Lymphocytes Day 3 
 
2.46 (1.29) 2.44 
(1.88) 
2.06 (1.54) 2.21 (2.39) 0.46 (0.37, 0.55) 
CRP Day 1 4 (0) 4 (0) 4 (0) 4 (0) 0.52 (0.45, 0.59) 
 
CRP Day 2 41.5 (39.5) 32.45 
(38.7) 
 
51 (51.1) 31.6 (44.5) 0.44 (0.37, 0.50) 
CRP Day 3 
 
49.95 (55) 50.55 (57) 93.05 (74) 39.25 (65) 0.52 (0.44, 0.59) 
bAPTT = biphasic activated partial thromboplastin time 
CRP = C-Reactive protein  
 
 
 
Table
Area under curve – Bacterial/Culture-negative against no infection/Viral (for all 
infections up to postoperative Day 28) 
Biomarker and post-
operative day of 
measurement 
Area under Curve 
(95%) 
Procalcitonin     Day 1 
                             Day 2 
                             Day 3 
0.62 (0.55, 0.68) 
0.58 (0.50, 0.66) 
  0.62 (0.52, 0.71) 
bAPTT                 Day 1 
                             Day 2 
                             Day 3 
0.49 (0.41, 0.56) 
0.52 (0.44, 0.59) 
   0.40 (0.34, 0.49) 
Neutrophils        Day 1 
                             Day 2 
                             Day 3  
0.50 (0.43, 0.58) 
0.63 (0.56, 0.71) 
0.58 (0.49, 0.67) 
Platelets             Day 1 
                             Day 2 
                             Day 3 
0.50 (0.42, 0.57) 
0.50 (0.43, 0.58) 
0.42 (0.34, 0.51) 
Lymphocytes     Day 1 
                             Day 2 
                             Day 3  
0.42 (0.35, 0.50) 
0.45 (0.37, 0.52) 
0.48 (0.39, 0.57) 
CRP                      Day 1 
                             Day 2 
                             Day 3 
0.52 (0.45, 0.59) 
0.45 (0.38, 0.52) 
0.55 (0.47, 0.63) 
 
Area under curve – Bacterial/Culture-negative against no infection/Viral (for all 
infections up to postoperative Day 7) 
Biomarker and post-
operative day of 
measurement 
Area under Curve 
(95%) 
Procalcitonin     Day 1 
                             Day 2 
                             Day 3 
0.59 (0.52, 0.65) 
0.57 (0.50, 0.65) 
  0.59 (0.50, 0.68) 
bAPTT                 Day 1 
                             Day 2 
                             Day 3 
0.49 (0.42, 0.56) 
0.51(0.44, 0.58) 
   0.39 (0.31, 0.47) 
Neutrophils        Day 1 
                             Day 2 
                             Day 3  
0.49 (0.42, 0.55) 
0.61 (0.53, 0.68) 
0.52 (0.43, 0.61) 
Platelets             Day 1 
                             Day 2 
                             Day 3 
0.50 (0.43, 0.56) 
0.51 (0.43, 0.58) 
0.43 (0.34, 0.51) 
Lymphocytes     Day 1 
                             Day 2 
                             Day 3  
0.47 (0.40, 0.54) 
0.47 (0.40, 0.55) 
0.46 (0.37, 0.55) 
CRP                      Day 1 
                             Day 2 
                             Day 3 
0.52 (0.45, 0.59) 
0.44 (0.37, 0.50) 
0.52 (0.44, 0.59) 
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